Active Biotech

Active Biotech (ACTI.ST) * Laquinimod - enrolment for the Allegro and Bravo Phase III studies proceeding * ANYARA - Phase III study proceeding - Promising median survival from Phase I study * TASQ - Phase II studies for treatment of prostate cancer in progress * 57-57 - Phase Ib study against SLE successfully concluded * RhuDex® - Phase IIa study against RA presented positive findings * Tomas Leanderson new CEO from September 1 * Net sales SEK 5.8 M (5.8) * Operating result SEK -104.7 M (-108.5) * Result after tax SEK -99.3 M (-112.1) * Result per share for the period amounted to SEK -2.07 (-2.46)

Active Biotech (ACTI.ST) Sven Andréasson has notified the Board of his wish to resign from the position as President & CEO of Active Biotech AB.

Active Biotech (ACTI.ST) Active Biotech AB (OMX NORDIC: ACTI), headquartered in Sweden, is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. Please visit www.activebiotech.com for more information.

Active Biotech (ACTI.ST) The number of shares and votes in Active Biotech has changed as a consequence of the recently completed rights issue.

Active Biotech (ACTI.ST) Lund, Sweden, June 24, 2008 - Active Biotech AB's (OMX Nordic:ACTI) collaboration partner MediGene AG (Frankfurt, Prime Standard: MDG) has achieved its objectives in a clinical phase IIa trial of the candidate drug RhuDex® for the treatment of rheumatoid arthritis.

Active Biotech (ACTI.ST) Tomorrow's issue of the scientific journal The Lancet, Volume 371, Issue 9630, includes an article covering Active Biotech's (OMX Nordic: ACTI) and Teva Pharmaceutical Industries Ltd's novel oral MS drug laquinimod. The article, entitled "Effect of Laquinimod on MRI-monitored disease activity in patients with RRMS: a multicenter, randomized, double-blind, placebo-controlled phase IIb study", will be available on www.thelancet.com. Laquinimod is currently in global clinical Phase III trials in the US, Europe and Israel.

Active Biotech (ACTI.ST) Active Biotech's new issue with preferential rights for the company's shareholders has been completed. Nordstjernan AB and MGA Holding AB subscribed for their respective preferential part of the new issue. In addition hereto, Nordstjernan AB, that guaranteed the new issue, subscribed for a further 150,087 shares, corresponding to 3.8 per cent of the shares issued. Accordingly, the new issue was subscribed for in its entirety. Following the new issue, Nordstjernan AB and MGA Holding AB own 15.3 per cent and 30.0 per cent, respectively, of the shares and votes in Active Biotech.